Avelumab
Brand: Bavencio (global) / Avelumab (IN/BD)
Anticancer
PD-L1 Immune Checkpoint Inhibitor
Pharmacokinetics
| Half-life | 156 hours |
| Clearance Route | other |
| Active Metabolites | no |
| Notes | RAW70: 10 mg/kg → ~700 mg every 2 weeks. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
Immune pneumonitis, hepatitis, colitis; infusion reactions common
Contraindications:
Severe autoimmune disease
Precautions:
Premedicate for infusion reactions; monitor immune toxicity; steroids for grade ≥3 events